Compare GSM & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSM | KURA |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 730.6M | 841.6M |
| IPO Year | 2015 | 2015 |
| Metric | GSM | KURA |
|---|---|---|
| Price | $3.29 | $10.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $6.00 | ★ $25.56 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | $23.36 | $28.28 |
| Revenue Next Year | $17.85 | $106.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $3.10 | $5.45 |
| 52 Week High | $5.74 | $12.49 |
| Indicator | GSM | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 32.69 | 63.42 |
| Support Level | N/A | $8.72 |
| Resistance Level | $4.68 | $11.29 |
| Average True Range (ATR) | 0.19 | 0.48 |
| MACD | -0.06 | 0.15 |
| Stochastic Oscillator | 16.27 | 84.57 |
Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's operating segments include Canada - Silicon Metals, Canada - Silicon Alloys, U.S. - Silicon Metals, U.S. - Silicon Alloys, Europe - Manganese Alloys, Europe - Silicon Metals, Europe - Silicon Alloys, South Africa - Silicon Metals, South Africa - Silicon Alloys, and Other segments. The primary raw materials the company uses to produce its electrometallurgy products include its coal and quartz mining operations and its silicon metal and ferroalloy production. The firm generates key revenue from Silicon metal and Manganese-based alloys.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.